Nagasaka M - Search Results

1

Clinicopathologic Features and Response to Therapy of NRG1 Fusion-Driven Lung Cancers: The eNRGy1 Global Multicenter Registry.

Drilon A, Duruisseaux M, Han JY, Ito M, Falcon C, Yang SR, Murciano-Goroff YR, Chen H, Okada M, Molina MA, Wislez M, Brun P, Dupont C, Branden E, Rossi G, Schrock A, Ali S, Gounant V, Magne F, Blum TG, Schram AM, Monnet I, Shih JY, Sabari J, Pérol M, Zhu VW, Nagasaka M, Doebele R, Camidge DR, Arcila M, Ou SI, Moro-Sibilot D, Rosell R, Muscarella LA, Liu SV, Cadranel J. Drilon A, et al. Among authors: nagasaka m. J Clin Oncol. 2021 Sep 1;39(25):2791-2802. doi: 10.1200/JCO.20.03307. Epub 2021 Jun 2. J Clin Oncol. 2021. PMID: 34077268 Free PMC article.

2

Role of chemotherapy and targeted therapy in early-stage non-small cell lung cancer.

Nagasaka M, Gadgeel SM. Nagasaka M, et al. Expert Rev Anticancer Ther. 2018 Jan;18(1):63-70. doi: 10.1080/14737140.2018.1409624. Epub 2017 Nov 26. Expert Rev Anticancer Ther. 2018. PMID: 29168933 Free PMC article. Review.

3

Responses in patients receiving sequential paclitaxel post progression on PD1 inhibitors.

Sukari A, Nagasaka M, Abdallah N. Sukari A, et al. Among authors: nagasaka m. Oral Oncol. 2018 May;80:100-102. doi: 10.1016/j.oraloncology.2018.03.011. Epub 2018 Mar 28. Oral Oncol. 2018. PMID: 29605290

4

The allure of 'ALUR'.

Nagasaka M, Zhu VW, Ou SI. Nagasaka M, et al. Ann Oncol. 2018 Jun 1;29(6):1344-1346. doi: 10.1093/annonc/mdy144. Ann Oncol. 2018. PMID: 29688274 Free article. No abstract available.

5

Liquid Biopsy to Identify Actionable Genomic Alterations.

Ou SI, Nagasaka M, Zhu VW. Ou SI, et al. Among authors: nagasaka m. Am Soc Clin Oncol Educ Book. 2018 May 23;38:978-997. doi: 10.1200/EDBK_199765. Am Soc Clin Oncol Educ Book. 2018. PMID: 30231331 Free PMC article. Review.

6

Neuregulin 1 Fusion-Positive NSCLC.

Nagasaka M, Ou SI. Nagasaka M, et al. J Thorac Oncol. 2019 Aug;14(8):1354-1359. doi: 10.1016/j.jtho.2019.05.015. Epub 2019 May 22. J Thorac Oncol. 2019. PMID: 31128291 Free article. No abstract available.

7

Immune checkpoint inhibitors: For how long do we need to release the brakes to achieve the optimum acceleration of immune-mediated anti-tumor response?

Sukari A, Nagasaka M. Sukari A, et al. Among authors: nagasaka m. Oral Oncol. 2020 Feb;101:104435. doi: 10.1016/j.oraloncology.2019.09.027. Epub 2019 Oct 18. Oral Oncol. 2020. PMID: 31635973

8

Evidence of NTRK1 Fusion as Resistance Mechanism to EGFR TKI in EGFR+ NSCLC: Results From a Large-Scale Survey of NTRK1 Fusions in Chinese Patients With Lung Cancer.

Xia H, Xue X, Ding H, Ou Q, Wu X, Nagasaka M, Shao YW, Hu X, Ou SI. Xia H, et al. Among authors: nagasaka m. Clin Lung Cancer. 2020 May;21(3):247-254. doi: 10.1016/j.cllc.2019.09.004. Epub 2019 Sep 26. Clin Lung Cancer. 2020. PMID: 31761448

9

KRAS G12C Game of Thrones, which direct KRAS inhibitor will claim the iron throne?

Nagasaka M, Li Y, Sukari A, Ou SI, Al-Hallak MN, Azmi AS. Nagasaka M, et al. Cancer Treat Rev. 2020 Mar;84:101974. doi: 10.1016/j.ctrv.2020.101974. Epub 2020 Jan 23. Cancer Treat Rev. 2020. PMID: 32014824 Free PMC article. Review.

10

Symptomatic CNS Radiation Necrosis Requiring Neurosurgical Resection During Treatment with Lorlatinib in ALK-Rearranged NSCLC: A Report of Two Cases.

Zhu VW, Nagasaka M, Kubota T, Raval K, Robinette N, Armas O, Al-Holou W, Ou SI. Zhu VW, et al. Among authors: nagasaka m. Lung Cancer (Auckl). 2020 Jan 14;11:13-18. doi: 10.2147/LCTT.S224991. eCollection 2020. Lung Cancer (Auckl). 2020. PMID: 32021525 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

516 results

Search Page